secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001104659-23-128782
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus secures up to $34.8M CEPI funding for MERS vaccine VTP-500 development
--------------------------------------------------------------------------------

- CEPI to provide $34.8M to advance VTP-500 through Phase II trials and develop 100,000-dose ready reserve.
- VTP-500 received EMA PRIME designation in December 2023, supporting accelerated regulatory review.
- Barinthus retains ownership of IP; will pay CEPI mid-single digit royalties on net sales and mid-double digit revenue share.
- Partnership with University of Oxford builds on ChAdOx1 platform used in Oxford-AstraZeneca COVID-19 vaccine.
- Equitable access commitments: LMICs receive vaccine at cost plus 10%; CEPI can support technology transfer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/0001104659-23-128782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/tm2333622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-128782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer